Rapt with MSB's performance today. Must admit I did not expect that this quickly. I like the manufacturing agreement. As I understand it, manufacturing is one of the sticking points with the FDA so if they have an agreement in place which will hopefully address some of the FDA concerns, that has to be a big plus. Also Novartis intends to initiate a Phase 3 study in non-COVID-19-related ARDS, which is another bonus. It's been quite a roller coaster this year.
